2 results about "Leukocytopenia" patented technology

This invention discloses a method for preparing pet stem cell exosomes, belonging to the field of animal medicine technology. This invention treats stem cells with an inducing agent to secrete exosomes with high TFR expression on their surface. These exosomes specifically target the conserved region of the NS1 gene, a non-structural protein of the parvovirus family, allowing the internally loaded siRNA and trefoil factor 3 to target and enter infected cells, directly inhibiting viral replication at the gene level to treat feline panleukopenia virus (FPV) and canine parvovirus infections and alleviate sequelae. This invention solves the problems of existing technologies, such as difficulty in targeting, lack of specific drugs, reliance on intensive supportive care leading to a short treatment window, inability to directly clear the virus, risk of cross-infection, and potential long-term sequelae. It has the potential to be applied to the preparation of drugs for treating canine parvovirus and feline panleukopenia.

The invention discloses a neutralizing monoclonal antibody for resisting feline panleucopenia virus and application of the neutralizing monoclonal antibody, and belongs to the technical field of bioengineering. The antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), and amino acid sequences of the heavy chain variable region (VH) and the light chain variable region (VL) are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2; the antibody is an IgG2a subtype and kappa light chain, can specifically bind to FPV VP2 protein, and effectively neutralizes infection of an F81 cell by an FPV-ZZ20230 strain under the dilution ratio of 1: 64. The invention also provides nucleic acid molecules (SEQ ID NO: 8-9) for coding the antibody, an expression vector, a host cell and a preparation method. The antibody can be used for preparing medicines for preventing or treating feline panleucopenia, and can also be used as a detection antibody for ELISA (enzyme-linked immuno sorbent assay), Western blot or indirect immunofluorescence (IFA) diagnostic kits. The antibody is clear in structure and high in neutralizing activity, does not need to be preserved by hybridoma, and has good clinical application and industrialization prospects.